Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy

scientific article published on April 2015

Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.18632/ONCOTARGET.3187
P932PMC publication ID4480758
P698PubMed publication ID25788260
P5875ResearchGate publication ID273782087

P2093author name stringLi Zhang
Fei Xu
Tao Qin
Li-Kun Chen
Xiao-Xiao Dinglin
Hai Liao
Jian-Zhong Liang
Shu-Xiang Ma
Wei-Dong Wei
Yin-Duo Zeng
P2860cites workMolecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.Q46797237
Temporal and gender-related trends in brain metastases from lung and breast cancer.Q48095538
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brainQ48203077
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.Q48256059
Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implicationsQ48372353
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutationQ48480145
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for CliniQ48543171
Quantitative Study of Blood.Brain Barrier Permeability Changes after Experimental Whole-Brain RadiationQ48552848
Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agentsQ48701500
Influence of radiation on the blood-brain barrier and optimum time of chemotherapyQ48844058
Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.Q51624503
Influence of radiation on the blood-brain barrier and optimum time of chemotherapyQ53659848
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapyQ54616855
Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical responseQ80438462
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancerQ84582496
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaQ27860881
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaQ27860904
Erlotinib in previously treated non-small-cell lung cancerQ29547546
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Q29620605
Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical casesQ30969216
Surgical strategies for metastatic lung cancerQ33642134
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibQ34566991
The seed and soil hypothesis: vascularisation and brain metastasesQ34571767
Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).Q34687074
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.Q35570245
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.Q35800614
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancerQ36625206
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancerQ37681047
Treatment of Brain Metastases: ChemotherapyQ37967507
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutationsQ40384212
The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancerQ41920792
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).Q42808426
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancerQ43060951
A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trialsQ44026405
Lung cancer with a single brain metastasis: therapeutic optionsQ44275075
Effect of gefitinib (ZD1839) on metastatic brain tumour.Q44912073
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trialQ44942613
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancerQ45098702
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicityQ45189921
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinomaQ45350153
Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment.Q45990408
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese populationQ46193107
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.Q46232500
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor geneQ46622914
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectlung cancerQ47912
adaptive radiation therapyQ180507
blood–brain barrierQ221694
P304page(s)8366-8376
P577publication date2015-04-01
P1433published inOncotargetQ1573155
P1476titleBlood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy
P478volume6

Reverse relations

cites work (P2860)
Q37742623A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
Q39002038Blood-brain barrier permeability of normal-appearing white matter in patients with vestibular schwannoma: A new hybrid approach for analysis of T1 -W DCE-MRI.
Q92637436Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
Q33649050Brain metastases from hepatocellular carcinoma: recent advances and future avenues
Q64071943Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors
Q38792519Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
Q92344477Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
Q36684011Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
Q47768004Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy
Q57801354Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations
Q33653615Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
Q58083388Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis
Q52709759Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
Q92326338EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
Q90385915Efficacy and Safety of Radiotherapy Plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data
Q46071509Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance
Q36212979Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80.
Q52591097Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
Q37121543Icotinib combined whole brain radiotherapy for patients with brain metastasis from lung adenocarcinoma harboring epidermal growth factor receptor mutation
Q89449724Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
Q92675544Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption
Q41954795Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
Q99406209Management of brain metastases: history and the present
Q38763104Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy
Q39337110Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
Q50927730Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer
Q51168062Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment
Q61136651Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases
Q47367544Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases
Q38985340State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer
Q54978262Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.
Q38738053Systemic therapies in the treatment of non-small-cell lung cancer brain metastases
Q55117380Targeted DNA sequencing of non-small cell lung cancer identifies mutations associated with brain metastases.
Q90641415The blood-brain barrier and blood-tumour barrier in brain tumours and metastases
Q89497176The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
Q92354826Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
Q31160473Treatment trends for patients with brain metastases: Does practice reflect the data?
Q98178296Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases